CRISPR Therapeutics Pulls Back Off Best Levels But Remains Firmly Positive

(RTTNews) - Shares of CRISPR Therapeutics (CRSP) have pulled back off their best levels of the day but continue to see significant strength in afternoon trading on Thursday. CRISPR is currently up by 3.2 percent.

CRISPR gapped open notably higher after the FDA lifted a clinical hold and accepted the Investigational New Drug application for the biopharmaceutical company's CTX001 for the treatment of sickle cell disease.

The company said CTX001 is an investigational, autologous, gene-edited hematopoietic stem cell therapy for patients suffering from severe hemoglobinopathies.